MedCap Acquires Rights to Syphilis Test
By Labmedica staff writers
Posted on 06 Dec 2004
The acquisition of the exclusive right to market and distribute a rapid test kit for the detection of syphilis has been announced by MedCap Corp. (Toronto, Canada).Posted on 06 Dec 2004
With early detection, syphilis is easily cured through a single dose of penicillin taken as an intramuscular injection. The World Health Organization (WHO, Geneva, Switzerland) estimates there are 340 million new cases of syphilis and other sexually transmitted diseases (STDs) each year. The largest number of new infections have occurred in South and Southeast Asia, followed by sub-Saharan Africa, Latin America, and the Caribbean islands. Individuals with syphilis have a three-to-five times increase in the risk of transmitting and acquiring an HIV infection when syphilis is present.
MedCap believes there is a virtually untouched market for a rapid diagnostic test kit related to the detection of syphilis that is easy to use, reasonably priced, and very accurate. The company anticipates that the acquisition of this syphilis test kit will result in substantial revenues.
Related Links:
MedCap Corp.
Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
